Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 13th World Drug Delivery Summit Montreal, Canada.

Day 1 :

Conference Series Drug Delivery 2019 International Conference Keynote Speaker Yavuz Selim Silay, photo

Yavuz Selim Silay is the Chairman of Istanbul Consulting Group. ICG was founded in 2013 and provided guidance to the Turkish ministry of health as part of a World Bank project. He is currently a Co-Founder of BioCube İstanbul Bioentrepreneurship & Innovation Center and Corporate Communication Director of Sumitomo Group/Expel İlaç Archem Diagnostices Endmed and Diagen. He previously managed the largest distributor of Siemens Healthcare in Turkey managing 250 employees and director of Avcılar Hospital R&D Center, Chief Medical Officer of Lifematrix GmbH. Previously he worked as the Market Access & Health Policy Director for AIFD in Turkey. Previously he worked as the Vice-President of Ipsen pharmaceutical and Director of Teva pharmaceutical in the USA managing large clinical trials as well as Investigator Initiated Trials and developing relationships with Key Opinion Leaders. Previously, he was the Associate Director at KV Pharmaceuticals and Director in Clinical Development department at Forest Laboratories. He earned his MD from the Faculty of Medicine, the University of Ankara in Ankara, Turkey. He completed a clinical internship at Baylor College of Medicine in Houston, followed by continued research training at The University of Texas MD Anderson Cancer Center in Houston. He recently completed his Executive MBA at the Olin Business School at Washington University in St. Louis


The world is being transformed by the 9 pillars of Industry 4.0. Industry 4.0 describes a future state of an industry characterized by complete digitization of economic and production flows. In the globally interconnected world of Industry 4.0, machines also interact with one another as a result of AI (Artificial Intelligence). Health 4.0 is also inevitable and the global impact of Health 4.0 will be discussed focusing on the changes in the pharmaceutical industry by 2030. The invention of computers, internet, social media, big data, artificial intelligence and other pillars in new technologies, are now redefining how we live, work, communicate including customer expectations, enabling businesses to meet these new expectations. Digital transformation, as this is commonly called, has immense potential to change consumer lives, create value for business and unlock broader societal benefits. The World Economic Forum launched the Digital Transformation Initiative in 2015 around the theme of the Fourth Industrial Revolution. Since its inception, the Initiative has analyzed the impact of digital transformation across 13 industries and five cross-industry topics, to identify the key themes that enable the value generated by digitalization to be captured for business and wider society. This analysis which is a good indicator of the impact of digital transformation and artificial intelligence will be discussed. Every industry has its nuances and contextual differences, but they all share certain accelerators, roadblocks to change. These include the innovator’s dilemma (the fear of cannibalizing existing revenue models), low technology adoption rates across organizations, conservative organizational cultures, and regulatory issues. Business and government leaders should continue to work towards addressing these challenges. If these challenges addressed, it can be applied consistently at all levels of business and government to help unlock the estimated $100 trillion of value digitalization could create over the next few years. Leveraging this framework globally is crucial. The goal should be enhancing the transformation process while providing a dynamic regulatory framework respecting the privacy of every individual.